Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731

View Full Paper
Ask AI
Bookmark
Share

Authors

RRRachel E. RauSeattle Children's HospitalACAndrew J. CarrollGoogle (United States)SCSusan J. ConwayCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Implication

Randomised trial improved disease-free survival in children with B-ALL, suggesting blinatumomab may change treatment strategies.

Key Points

  • This research aims to determine the impact of blinatumomab on disease-free survival and prognostic factors in children with B-ALL.
  • Enrolled newly diagnosed NCI standard risk B-ALL patients aged 1 to <10 years.
  • Patients were randomized to standard chemotherapy or chemotherapy with blinatumomab.
  • Prognostic significance of traditional variables was compared between treatment arms.
  • 4-year disease-free survival was 94.8% for blinatumomab arms versus 86.9% for control arms.
  • BM relapses significantly reduced in blinatumomab arms compared to control arms.
  • Hispanic ethnicity had no adverse impact in blinatumomab arms, indicating altered prognostic significance.

Cite This Study

Rau et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d063https://doi.org/10.1182/blood-2025-758
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026
  2. 2Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse2023 · 111 citations
  3. 3Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  4. 4Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024
  5. 5Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia2026 · 2 citations